Atara Biotherapeutics (ATRA) AI Stock Analysis

• Market Cap: $62.72M
• Dividend Yield: N/A
• Average Volume (3M): 42.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: 475.53%
• EPS Growth: 89.94%
• Country: US
• Employees: 153
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 3.50
• Shares Outstanding: 6,795,628
• 10 Day Avg. Volume: 25,857
• 30 Day Avg. Volume: 42,295
• PEG Ratio: <0.01
• Price to Book (P/B): 2.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.22
• Enterprise Value/Market Cap: 4.99
• Enterprise Value/Revenue: 0.64
• Enterprise Value/Gross Profit: 1.95
• Enterprise Value/Ebitda: -0.83
• 1Y Price Target: $12.50
• Price Target Upside: 35.43% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 50 Neutral
• Price Target: $9.50 ▲(2.93%Upside)

Atara Biotherapeutics' overall stock score reflects significant financial distress and valuation challenges, partially offset by favorable technical indicators and regulatory progress. The company's financial instability and negative earnings outlook are the most significant risks, while recent FDA clearance provides a positive development.

Positive Factors

FDA Approval Process

No additional data were requested by FDA for BLA resubmission.

Strategic Partnerships

Atara has completed the transfer of all EBVALLO manufacturing to Pierre Fabre, and is solely focusing on BLA resubmission, with additional milestone payments on FDA approval.

Negative Factors

Financial Constraints

Atara announced a reduction in its workforce that will impact approximately 50% of its current employees.

Funding Challenges

Risks include inability to resubmit the tab-cel BLA in a timely manner, rejection of the tab-cel BLA resubmission by the FDA, and setbacks with other pipeline candidates.

Atara Biotherapeutics Business Overview & Revenue Model

Company Description

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

How the Company Makes Money

Atara Biotherapeutics generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships typically involve upfront payments, milestone payments contingent on the achievement of specific development or regulatory goals, and royalties based on product sales. Additionally, Atara may receive funding from grants or government sources to support its research and development efforts. The company focuses on advancing its product candidates through clinical trials to achieve regulatory approval, which would enable it to commercialize its therapies and generate direct sales revenue.

Atara Biotherapeutics Financial Statement Overview

Summary

Atara Biotherapeutics is in a challenging financial position, with significant losses and high leverage. The company is showing revenue growth, but profitability and cash flow remain major concerns. The negative equity position and high liabilities suggest financial instability, posing potential risks for continued operations.

Income Statement

The company has shown significant improvement in revenue over time, particularly with a notable increase in the latest TTM period. However, the company remains unprofitable with negative net income, EBIT, and EBITDA margins, which indicate ongoing operational challenges and high costs relative to revenue.

Balance Sheet

The company has a negative stockholders' equity, which is a significant concern. The debt-to-equity ratio cannot be calculated due to negative equity, but high total liabilities relative to assets suggest high leverage. This financial instability raises concerns about the company's ability to manage its obligations.

Cash Flow

The company has consistently negative free cash flow, reflecting challenges in generating cash from operations. The operating cash flow to net income ratio is slightly favorable, indicating better cash management than net income would suggest, but overall cash flow dynamics remain weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	199.73M	128.94M	8.57M	63.57M	20.34M	0.00
Gross Profit	160.27M	107.93M	-313.00K	49.01M	8.96M	-9.87M
EBITDA	-5.74M	-75.75M	-266.00M	-213.72M	-331.12M	-296.74M
Net Income	-15.64M	-85.40M	-276.13M	-2.28B	-3.40B	-3.07B
Balance Sheet
Total Assets	62.04M	109.10M	165.50M	376.42M	468.13M	588.12M
Cash, Cash Equivalents and Short-Term Investments	13.84M	42.50M	51.73M	242.82M	371.07M	500.66M
Total Debt	26.71M	43.83M	57.87M	71.70M	28.27M	13.04M
Total Liabilities	117.11M	206.38M	264.74M	249.78M	188.51M	125.78M
Stockholders Equity	-55.07M	-97.28M	-99.23M	126.64M	279.61M	462.34M
Cash Flow
Free Cash Flow	-67.36M	-68.96M	-194.20M	-274.62M	-231.10M	-185.27M
Operating Cash Flow	-67.24M	-68.72M	-192.98M	-270.43M	-220.52M	-180.76M
Investing Cash Flow	11.11M	8.62M	123.87M	202.96M	22.26M	-120.73M
Financing Cash Flow	34.89M	59.28M	2.01M	53.08M	103.94M	427.57M

Atara Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.23
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATRA, the sentiment is Positive. The current price of 9.23 is above the 20-day moving average (MA) of 8.39, above the 50-day MA of 7.95, and above the 200-day MA of 8.84, indicating a bullish trend. The MACD of 0.33 indicates Negative momentum. The RSI at 64.11 is Neutral, neither overbought nor oversold. The STOCH value of 88.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATRA.

Atara Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.51B	0.24	-62.67%	2.30%	16.09%	0.95%
ATRA	50 Neutral	$62.72M	―	1063.61%	―	475.53%	89.94%
NRXP	45 Neutral	$63.78M	―	108.28%	―	―	41.01%
LTRN	45 Neutral	$37.85M	―	-75.66%	―	―	-31.16%
XFOR	44 Neutral	$9.09M	0.64	121.75%	―	―	―
KPTI	43 Neutral	$39.31M	―	41.08%	―	1.19%	61.65%
HOWL	40 Underperform	$48.46M	―	-82.81%	―	-92.95%	-50.02%

Atara Biotherapeutics Corporate Events

Atara Biotherapeutics Holds Annual Stockholders Meeting

On June 10, 2025, Atara Biotherapeutics held its annual stockholders meeting, where several key decisions were made. The election of directors resulted in the appointment of three nominees to serve until 2028. Additionally, stockholders approved the executive compensation plan and decided to hold annual advisory votes on this matter. Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

Atara Biotherapeutics Announces $16M Stock Offering

On May 14, 2024, Atara Biotherapeutics entered into an underwriting agreement with TD Securities (USA) LLC for an underwritten registered direct offering of its common stock and pre-funded warrants, expected to generate approximately $16 million in gross proceeds. The company plans to use the net proceeds to support its biologics license application for tab-cel and for general corporate purposes, with the offering set to close on May 16, 2025.

The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

Atara Biotherapeutics Appoints New Board Members Amid Restructuring

On May 14, 2025, Atara Biotherapeutics announced the appointment of James Huang and Nachi Subramanian to its Board of Directors following a direct offering of shares and warrants to institutional investors, expected to close on May 16, 2025. The company aims to extend its cash runway through the first quarter of 2026 with the $16 million proceeds, supporting its ongoing activities for potential BLA approval. Atara has transferred manufacturing responsibilities to Pierre Fabre Laboratories, significantly reducing operating expenses, and has paused its CAR T programs while undergoing organizational restructuring, including a 30% workforce reduction.

The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

Atara Biotherapeutics Announces Major Workforce Reduction

On May 12, 2025, Atara Biotherapeutics, Inc. announced a significant workforce reduction, affecting approximately 30% of its employees, with the aim of retaining around 23 essential staff members to focus on strategic priorities. The company anticipates completing this reduction by August 2025, incurring approximately $1.4 million in severance and related benefits, primarily as one-time cash charges, with further details to be disclosed in their upcoming quarterly report.

The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

FDA Lifts Hold on Atara’s EBVALLO Program

On May 5, 2025, Atara Biotherapeutics announced that the FDA lifted the clinical hold on its EBVALLO™ (tabelecleucel) program, initially placed in January 2025 due to GMP compliance issues at a third-party manufacturing facility. This decision allows Atara to resume its Phase 3 ALLELE clinical study and a Phase 2 label-expansion study for patients with EBV-associated post-transplant lymphoproliferative disease. Additionally, the FDA granted a Type A meeting to discuss the path forward for resubmitting the Biologics License Application (BLA) for EBVALLO™. Atara has temporarily paused its strategic option evaluation pending clarity on the BLA resubmission timeline.